WO2024055983A1 - Composition de protéine de graine de citrouille et son utilisation - Google Patents

Composition de protéine de graine de citrouille et son utilisation Download PDF

Info

Publication number
WO2024055983A1
WO2024055983A1 PCT/CN2023/118501 CN2023118501W WO2024055983A1 WO 2024055983 A1 WO2024055983 A1 WO 2024055983A1 CN 2023118501 W CN2023118501 W CN 2023118501W WO 2024055983 A1 WO2024055983 A1 WO 2024055983A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
composition
subject
intestinal
pumpkin seed
Prior art date
Application number
PCT/CN2023/118501
Other languages
English (en)
Chinese (zh)
Inventor
江龙
吴婧
廖琪林
Original Assignee
南京纽邦生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南京纽邦生物科技有限公司 filed Critical 南京纽邦生物科技有限公司
Publication of WO2024055983A1 publication Critical patent/WO2024055983A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/174—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/38—Other non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/185—Vegetable proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention belongs to the technical field of health food and dietary supplements, and specifically relates to compositions of pumpkin seed protein or its isolated protein, hydrolyzed protein, concentrated protein and its use in medicines, nutritional supplements, health products, food, beverages and animal feeds. Related applications.
  • Intestinal flora plays a very important role in the human body. It is regarded as another "hidden organ” of the human body and carries the human body's "second gene". Therefore, the human body is also described as a super organism. Intestinal flora regulate intestinal homeostasis through interaction with the host; imbalance of intestinal homeostasis caused by various reasons will affect human health and lead to various diseases.
  • Lactobacillus acidophilus mainly exists in the small intestine and releases lactic acid, acetic acid and some antibiotics that act on harmful bacteria. It is an intestinal probiotic; Streptococcus thermophilus is an oxygen-consuming Gram-positive bacterium that exists in the human body. A kind of beneficial bacteria in the intestines that can help people with lactose intolerance digest lactose; Bifidobacterium is an important intestinal beneficial microorganism, which has nutritional, anti-tumor and immune-enhancing effects on human health, plays a biological barrier, and improves gastrointestinal function. It has various physiological functions such as intestinal function, anti-aging, etc. Typical representatives include Bifidobacterium longum, Bifidobacterium lactis, etc. Escherichia coli is an opportunistic pathogen and is a gram-negative bacterium. Under certain conditions, it can cause gastrointestinal infection or urinary tract and other local tissue and organ infections in humans and animals.
  • Intestinal probiotics can synthesize a variety of vitamins (mainly vitamins K and B), participate in the digestion of food (such as carbohydrates), produce lactic acid, promote intestinal peristalsis, inhibit the growth of pathogenic bacteria and decompose harmful substances, and activate the immune system , maintaining the balance of intestinal flora is indispensable to human health.
  • vitamins mainly vitamins K and B
  • the regulation of intestinal flora and the improvement of intestinal microenvironment can be achieved through exogenous supplementation of probiotics; probiotics must reach a sufficient quantity to be effective, and have high requirements on preparation technology, storage conditions, price, etc.
  • Pathogenic bacteria produce pathogenic substances and cause host infection. In order to maintain intestinal health, it is necessary to promote the proliferation of intestinal probiotics and reduce the number of intestinal pathogenic bacteria.
  • pumpkin seeds contain a large amount of fat, protein, phytosterols, various minerals and other nutrients, and their health value has been recognized around the world.
  • people have begun to study the extraction, isolation and utilization of pumpkin seed protein from pumpkin seeds.
  • Studies have shown that the antifungal protein extracted from naked pumpkin seeds has significant growth inhibitory activity against common agricultural pathogenic bacteria; the activity of extracted from pumpkin seeds The protein has N-glycosidase activity and shows a strong inhibitory effect on the proliferation of human melanoma cells. These studies indicate that pumpkin seed protein has certain physiological activity.
  • pumpkin seed protein has high nutritional value and has some applications in other aspects, its development and utilization in health food and medicine are not enough. Protein, as an important nutrient, has received increasing attention for its impact on intestinal health. Intestinal flora can participate in the body's protein metabolism. Food protein will affect the composition and balance of the intestinal flora, and changes in the intestinal flora affect the body's utilization of protein. If pumpkin seed protein with the ability to regulate intestinal health can be extracted, the application scope of pumpkin seed protein can be expanded, and multifunctional peptide resources can be enriched, which is also crucial for improving intestinal health and/or preventing chronic diseases and complications.
  • the present invention provides a culture medium that can promote the proliferation of intestinal probiotics (beneficial bacteria), reduce pathogenic bacteria (harmful bacteria), and effectively reduce the number of bacteria containing Lactobacillus acidophilus, Streptococcus thermophilus and Bifidobacterium
  • the pH value promotes the production of short-chain fatty acids, thereby inhibiting the growth of spoilage bacteria, promoting gastrointestinal motility and the growth of probiotics, and regulating the composition and application of pumpkin seed protein for intestinal health.
  • the pumpkin seed protein of the present invention can be added to various products according to different needs or compatible with other ingredients; the protein component is easy to use and has safe ingredients.
  • the pumpkin seed protein can be isolated pumpkin seed protein, concentrated pumpkin seed protein or hydrolyzed pumpkin. Any one or more types of seed proteins.
  • the invention provides a method of increasing the level of a first intestinal microbiota in a subject, comprising: administering to the subject a composition containing pumpkin seed protein or its isolate, hydrolyzed protein, or protein concentrate. ;
  • the composition effectively increases the level of the first intestinal microbiota in the subject;
  • the first intestinal microbiota is selected from one or more of the following: Lactobacillus acidophilus, Streptococcus thermophilus, Bifidobacterium longum, Bifidobacterium lactis.
  • the above method further includes reducing the level of E. coli in the subject.
  • the first intestinal microbiota are intestinal probiotics.
  • the composition is formulated as a nutritional supplement, food, beverage, animal feed, or pharmaceutical.
  • compositions are prepared as solid or liquid formulations.
  • compositions are in the form of suppositories, tablets, pills, granules, powders, films, capsules, beverages, aerosols, spirits, tinctures, tonics, liquid suspensions, or syrups.
  • the composition is administered to the subject at a dosage of 0.1-500g, preferably 1-400g, 2-300g, 3-200g, 5-100g per day.
  • the composition can be administered to the subject at a dose of 0.1-10g/kg, 0.5-5g/kg, 1-3g/kg per day.
  • the present invention provides a composition containing pumpkin seed protein or its protein isolate, hydrolyzed protein, or concentrated protein in the manufacture of a nutritional supplement for increasing the level of the first intestinal microbiota in a subject
  • the first intestinal microflora is selected from one or more of the following: Lactobacillus acidophilus, Streptococcus thermophilus, Bifidobacterium longum, and Bifidobacterium lactis.
  • the first intestinal microbiota are intestinal probiotics.
  • the above uses further include reducing the level of E. coli in the subject.
  • the composition is administered to the subject at a dose of 0.1-500g, preferably 1-400g, 2-300g, 3-200g, 5-100g per day; the composition is effective to increase the first intestinal tract in the subject level of the microbiota.
  • the composition can be administered to the subject at a dose of 0.1-10g/kg, 0.5-5g/kg, 1-3g/kg per day.
  • compositions are prepared as solid or liquid formulations.
  • compositions are in the form of suppositories, tablets, pills, granules, powders, films, capsules, beverages, aerosols, spirits, tinctures, tonics, liquid suspensions, or syrups.
  • the pumpkin seed protein of the present invention is easily absorbed directly by the intestinal tract, can promote the proliferation of intestinal probiotics, reduce the number of intestinal pathogenic bacteria, effectively reduce the pH value of the culture medium containing Lactobacillus acidophilus, Streptococcus thermophilus and Bifidobacterium, and promote The production of short-chain fatty acids, thereby regulating intestinal health and/or overall health; while discovering new functions and nutritional properties of pumpkin seed protein, increasing the added value of pumpkin seed protein utilization.
  • Figure 1A is a graph showing the growth curves of Lactobacillus acidophilus and Streptococcus thermophilus in corresponding media with or without pumpkin seed protein.
  • Figure 1B is a graph showing the growth curves of two bifidobacteria in corresponding media with or without pumpkin seed protein.
  • Figure 2 is a comparison chart of the log number of colonies of E. coli.
  • Figure 3 is a comparison chart of log colony values of Lactobacillus acidophilus, Streptococcus thermophilus, Bifidobacterium longum and Bifidobacterium lactis.
  • the term "comprises” or “includes” or variations thereof means where the term is used in its non-limiting sense to include the items following the word but not to exclude items not specifically mentioned. It also includes the more restrictive verbs 'consist essentially of' and 'consist of'.
  • the terms “subject” or “individual” are used interchangeably to refer to any subject to whom the methods and compositions of the present disclosure may be applied or administered. It is possible for a subject to suffer from a disease or disorder, but the subject need not be ill to benefit from the methods and compositions of the present disclosure. A subject may need to improve his or her gut and/or overall health, but a subject may also have a generally healthy gut and wish to maintain or further improve his or her gut and/or overall health. Accordingly, any subject can take the disclosed compositions or be the recipient of the disclosed methods. As used herein, the term “subject” refers to animals (eg, birds, reptiles, and mammals).
  • subjects may include non-primates (e.g., camels, donkeys, zebras, cows, horses, cats, dogs, rats, and mice) and primates (e.g., monkeys, Chimpanzees, humans) mammals.
  • non-primates e.g., camels, donkeys, zebras, cows, horses, cats, dogs, rats, and mice
  • primates e.g., monkeys, Chimpanzees, humans
  • the subject may be a non-human mammal. In other embodiments, the subject can be a human.
  • compositions of the present invention may be administered in a variety of ways to achieve the desired effect, including orally, intragastric and parenterally (meaning intravenous and intraarterial as well as other suitable parenteral routes) and the like.
  • protein when describing protein concentration, protein molecular weight distribution, protein solubility and protein amino acid content is defined as native protein structure or denatured protein structure or fragments thereof; shall be interpreted broadly and includes intact proteins, polypeptides , oligopeptides, amino acids and mixtures thereof.
  • Hydrolyzed protein protein hydrolyzate
  • Protein isolate protein isolate
  • Protein concentrate protein concentrate
  • the term "effective amount” refers to the amount required to achieve the effect as taught herein. Effective amounts herein include, but are not limited to, amounts necessary to increase intestinal probiotics in a subject; and/or to reduce intestinal pathogenic bacteria in a subject; and/or to improve intestinal health and/or overall The amount necessary for health.
  • a suitable single dose size is one that achieves the above effects when administered one or more times over a suitable period of time.
  • compositions or agents, materials or combinations of compositions and/or dosage forms thereof which are suitable for contact with human and animal tissues, are compatible with the other ingredients of the composition, and do not exhibit undue toxicity, irritation, allergic reaction or Other problems or complications, commensurate with a reasonable benefit/risk ratio.
  • the present application found that administration of pumpkin seed protein significantly increased the levels of the first intestinal microbiota in the subjects while reducing the levels of E. coli in the subjects.
  • the present invention and embodiments relate to methods and compositions using "pumpkin seed protein-containing" compositions and/or "pumpkin seed protein enhanced” compositions, wherein the pumpkin seed protein-containing compositions comprise pumpkin seed protein-containing compositions Or any combination of protein isolate, protein hydrolyzate, or protein concentrate.
  • the methods of the present invention comprise the daily administration of at least 0.1 g, typically 0.1-500 g, 1-400 g, preferably 2-300 g, 3-200 g, 5-100 g, of a pumpkin seed protein-containing composition, depending on the specific formulation and form .
  • the amount to be administered can also be 0.1-10g/kg, 0.5-5g/kg, 1-3g/kg of subject's body weight per day, depending on factors such as subject's sensitivity, age, gender and weight, idiosyncratic reactions, etc. Variety.
  • One or more doses may be administered one or more times daily or at a suitable frequency for any period of time. For example, an effective dose may be administered daily for one day, several days, multiple days, or indefinitely.
  • the pumpkin seed protein-containing composition of the present invention may be formulated as a nutritional or dietary supplement, a (medical) food, an animal feed or a pharmaceutical composition, in liquid or solid form, and may optionally also include nutritional or a pharmaceutically acceptable carrier.
  • the compositions when in solid form, the compositions may be formulated as snack bars, yogurt, lozenges, tablets or capsules.
  • the compositions when in liquid form, the compositions may be formulated as tinctures, soft gel capsules, liquid capsules, syrups, carbonated beverages, brewed beverages (eg, coffee or tea), juices, energy drinks, sports drinks, or flavored waters.
  • pumpkin seed protein-containing compositions and formulations may also be used for veterinary purposes (e.g., animal feed for domestic companion animals ("pets") or animal feed for farm animals.
  • the pumpkin seed protein-containing composition may also be provided in the form of a bulk product (for example, in an amount equal to or greater than 100 g, equal to or greater than 1000 g, or equal to or greater than 10 kg) for the production of nutritional supplements, (medical) Food, animal feed or pharmaceuticals.
  • contemplated methods of administering a pumpkin seed protein-containing composition include administering at least one probiotic microorganism simultaneously with or subsequent to administration of a pumpkin seed protein-containing composition.
  • the composition can also be combined with arabinoxylan (AX), arabinoxylan oligosaccharide (AXOS), xylo-oligosaccharide (XOS), fructooligosaccharide (FOS), galacto-oligosaccharide (GOS), inulin and/or one or a combination of two prebiotics in pectin.
  • the pumpkin seed protein-containing compositions of the present invention may be combined with health additives to increase the breadth of health benefits.
  • Health additives may be added to the pumpkin seed protein-containing composition in any combination depending on the form of the composition and considerations of desired health effects and product cost.
  • Exemplary additives that may be combined with pumpkin seed protein-containing compositions include superoxide dismutase (SOD), compositions containing activators of SOD, foods containing bioavailable SOD, or extracts thereof (e.g., sprouted wheat, Wheatgrass, encapsulated (lipid and/or protein encapsulated) cantaloupe, rye, barley, barley grass, broccoli sprouts, kale, Brussels sprouts and curcuminoids (e.g.
  • turmeric copper iodide (CuI ), selenium (Se), fulvic acid, foods containing fulvic acid or their extracts (e.g. potatoes, radish, beets, carrots, root vegetables, blackstrap molasses and shilajit), coenzyme Q10 (ubiquinone) or pyrrolo Quinoline quinone (PQQ).
  • CuI copper iodide
  • Se selenium
  • fulvic acid foods containing fulvic acid or their extracts
  • foods containing fulvic acid or their extracts e.g. potatoes, radish, beets, carrots, root vegetables, blackstrap molasses and shilajit
  • coenzyme Q10 ubiquinone
  • PQQQ pyrrolo Quinoline quinone
  • each activated strain into each culture medium with or without the addition of pumpkin seed protein or its isolated protein, hydrolyzed protein, or concentrated protein at an inoculum volume of 2%: Lactobacillus acidophilus (L. acid) 563 in MRS liquid
  • the culture medium was statically cultured at 37°C; Streptococcus thermophilus (S.thermophilus) 176 was cultured statically in Eliker medium at 42°C; Bifidobacterium longum (Bifido.longum) BB536 and Bifidobacterium lactis ( Bifido.
  • lactis BB12 were cultured anaerobically at 37°C in mMRS medium (MRS medium containing 0.05% L-cysteine hydrochloride). The cultures were cultured to a certain point in the logarithmic phase, and then the pH values of the two fermentation broths in each group were measured, and viable bacteria were counted. The results are shown in Table 1.
  • pumpkin seed protein promotes the production of short-chain fatty acids, thereby inhibiting the growth of spoilage bacteria, promoting gastrointestinal motility and the growth of probiotics; the number of viable bacteria in the protein group increased, indicating that pumpkin seed protein can effectively increase the growth rate of Lactobacillus acidophilus, Viable bacterial counts of Streptococcus thermophilus, Bifidobacterium longum, and Bifidobacterium lactis.
  • Figure 1A is a growth curve diagram of Lactobacillus acidophilus 563 and Streptococcus thermophilus 176 in corresponding media with or without the addition of pumpkin seed protein or its isolated protein, hydrolyzed protein, or concentrated protein.
  • Figure 1B is a graph showing the growth curves of Bifidobacterium longum BB536 and Bifidobacterium lactis BB12 in corresponding media with or without the addition of pumpkin seed protein or its isolated protein, hydrolyzed protein, or concentrated protein.
  • Figure 1A when pumpkin seed protein was added for culture, the OD values of Lactobacillus acidophilus 563 and Streptococcus thermophilus 176 changed compared to when pumpkin seed protein was not added.
  • the blank control group was fed normal feed and an equal volume of distilled water
  • the pumpkin seed protein group was fed pumpkin seed protein in addition to normal feed.
  • the pumpkin seed protein group was given about 1-3g/kg of pumpkin seed protein or its isolated protein, hydrolyzed protein, or concentrated protein every day.
  • mice After 30 days of feeding, the feces of the two groups of mice were collected for intestinal flora culture and analysis. Manually collect fresh fecal balls from the end of the rat rectum, dilute them to 10 -9 , spot them on various culture media, and culture them under appropriate conditions. After culturing, high-throughput sequencing and metabolomic analysis of 16S rDNA of intestinal flora were performed. The number of bacteria was counted in colony forming units lg (CFU/g), and the changes in bacterial colonies were comparatively analyzed. The results are shown in Figures 2 and 3.
  • Figure 2 is a comparison chart of the log number of colonies of E. coli in the blank group and the pumpkin seed protein treatment group. As shown in Figure 2, compared with the blank group, the E. coli in the pumpkin seed protein group decreased by 12.07%, indicating that pumpkin seed protein can effectively reduce the content of E. coli.
  • Figure 3 is a comparison chart of the logarithmic colony values of Lactobacillus acidophilus, Streptococcus thermophilus, Bifidobacterium longum and Bifidobacterium lactis in the blank group and the pumpkin seed protein treatment group.
  • Lactobacillus acidophilus, Streptococcus thermophilus, Bifidobacterium longum and Bifidobacterium lactis increased by 4.97%, 11.66%, 5.65% and 5.58% respectively in the pumpkin seed protein group. , indicating that pumpkin seed protein can effectively promote the in vivo proliferation of Lactobacillus acidophilus, Streptococcus thermophilus, Bifidobacterium longum and Bifidobacterium lactis.
  • the content of other intestinal probiotics can also be increased, such as Lactobacillus rhamnosus, Bifidobacterium adolescentis, Lactobacillus bulgaricus, etc.; the content of other intestinal pathogenic bacteria can be reduced, Such as Staphylococcus aureus, Pseudomonas aeruginosa, Salmonella, etc. This allows the levels of gut microbiota to be maintained and/or restored to near-normal levels, which is highly beneficial for maintaining gut health and/or overall health.
  • the pumpkin seed protein of the present invention can promote the proliferation of intestinal probiotics, reduce the number of pathogenic bacteria, effectively reduce the pH value of the culture medium containing Lactobacillus acidophilus, Streptococcus thermophilus and Bifidobacterium, promote the production of short-chain fatty acids, and thereby regulate the intestinal tract.
  • Tao Health can be combined with different ingredients according to different needs. It can not only meet the needs of vegetarians but also regulate intestinal health and/or overall health; it provides a basis for the future development and utilization of pharmaceuticals and health products containing pumpkin seed protein and corresponding peptides. and laid the foundation for the production and application of various products.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Une composition d'une protéine de graine de citrouille ou d'une protéine isolée, un hydrolysat de protéine ou une protéine concentrée de celle-ci, et son utilisation dans la préparation d'un médicament, d'un produit nutritionnel, d'un produit de soins de santé, d'un produit alimentaire, d'une boisson et d'une alimentation animale pour réguler la flore intestinale. La flore intestinale est choisie parmi un ou plusieurs des éléments suivants : Lactobacillus acidophilus, Streptococcus thermophilus, Bifidobacterium longum et Bifidobacterium lactis.
PCT/CN2023/118501 2022-09-14 2023-09-13 Composition de protéine de graine de citrouille et son utilisation WO2024055983A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202211114142.1 2022-09-14
CN202211114142.1A CN117731007A (zh) 2022-09-14 2022-09-14 南瓜籽蛋白组合物和其应用

Publications (1)

Publication Number Publication Date
WO2024055983A1 true WO2024055983A1 (fr) 2024-03-21

Family

ID=90274289

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/118501 WO2024055983A1 (fr) 2022-09-14 2023-09-13 Composition de protéine de graine de citrouille et son utilisation

Country Status (2)

Country Link
CN (1) CN117731007A (fr)
WO (1) WO2024055983A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105520151A (zh) * 2016-01-26 2016-04-27 青岛森淼实业有限公司 果蔬蛋白粉营养补充剂及其制备方法
CN106820156A (zh) * 2017-02-17 2017-06-13 福建康是美生物科技有限公司 一种调节肠道菌群健康的益生菌组合物
CN108310238A (zh) * 2018-03-15 2018-07-24 武汉虹辰远荣生物制品有限公司 一种防治腹泻的益生菌组合物
CN109662311A (zh) * 2018-12-13 2019-04-23 武汉森澜生物科技有限公司 具有润肠通便功能的酵素及其制备方法和应用
CN111019990A (zh) * 2018-10-09 2020-04-17 杏辉天力（杭州）药业有限公司 一种南瓜籽肽粉及其制备方法和用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105520151A (zh) * 2016-01-26 2016-04-27 青岛森淼实业有限公司 果蔬蛋白粉营养补充剂及其制备方法
CN106820156A (zh) * 2017-02-17 2017-06-13 福建康是美生物科技有限公司 一种调节肠道菌群健康的益生菌组合物
CN108310238A (zh) * 2018-03-15 2018-07-24 武汉虹辰远荣生物制品有限公司 一种防治腹泻的益生菌组合物
CN111019990A (zh) * 2018-10-09 2020-04-17 杏辉天力（杭州）药业有限公司 一种南瓜籽肽粉及其制备方法和用途
CN109662311A (zh) * 2018-12-13 2019-04-23 武汉森澜生物科技有限公司 具有润肠通便功能的酵素及其制备方法和应用

Also Published As

Publication number Publication date
CN117731007A (zh) 2024-03-22

Similar Documents

Publication Publication Date Title
EP1945235B1 (fr) Des probiotiques pour influencer le métabolisme des graisses et l'obésité
CN101486986B (zh) 一种嗜酸乳杆菌冻干菌粉的制备方法
JP5903380B2 (ja) 経口用皮膚性状改善剤
US20080102061A1 (en) Use hydrolyzed medium containing microorganisms medicinally
US20120020942A1 (en) Novel Lactobacillus Strains And Their Use Against Helicobacter Pylori
WO2019112054A1 (fr) Nouvelle bactérie bifidobacterium, et composition contenant cette bactérie
WO2011034166A1 (fr) Agent anti-obésité, aliment ou boisson anti-obésité, agent d'amélioration de tolérance au glucose et aliment ou boisson pour l'amélioration de la tolérance au glucose
TW200944215A (en) Lactobacillus isolates having anti-inflammatory activities and uses of the same
CN102245191A (zh) 用于改善口腔健康的组合物和方法
EP3725321A1 (fr) Composition contenant une bactérie appartenant au genre bifidobacterium en tant que substance active
KR20140140387A (ko) 나노형 김치 유산균
JP7296454B2 (ja) 炎症関連胃腸障害の処置のためのプロバイオティクスの組み合わせ
JP2016520305A (ja) 消化管微生物叢中のラクノスピラ科細菌及び体重との関連性
CN111011856A (zh) 用于缓解胃病的组合物、其制备方法及用于缓解胃病的食品
TW201542216A (zh) 新穎副乾酪乳桿菌（Ｌａｃｔｏｂａｃｉｌｌｕｓ ｐａｒａｃａｓｅｉ）株
JP5592640B2 (ja) 乳酸菌発酵ローヤルゼリーを含有する抗ストレス剤、その製造方法、視床下部−下垂体−副腎皮質系の活動抑制剤、及び交感神経−副腎髄質系の活動抑制剤
CN111212575A (zh) 肌肉增量用组合物
CN110692885A (zh) 一种用于缓解便秘的益生菌保健饮料
KR101545551B1 (ko) 인슐린 저항성 개선 효능을 갖는 7종의 유산균 복합균주를 유효성분으로 함유하는 조성물
WO2019112053A1 (fr) Nouvelle bactérie bifidobacterium, et composition contenant cette bactérie
WO2024027401A1 (fr) Procédé et composition pour améliorer le microbiote intestinal
AU2004208084A1 (en) New strains of Bifidobacterium having the ability to produce glutamine
CN111685255B (zh) 一种增强免疫功能的益生菌固体饮料及其制备方法
KR20220018964A (ko) 더 큰 내약성 및 연장된 저장 수명을 위한 미생물 조성물 및 방법
WO2024055983A1 (fr) Composition de protéine de graine de citrouille et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23864715

Country of ref document: EP

Kind code of ref document: A1